摘要
目的探讨血浆肿瘤型M2丙酮酸激酶（TuM2-PK）、神经元特异烯醇化酶（NSE）和细胞角蛋白19（CYFRA21-1）联合测定对肺癌诊断的临床意义。方法用酶联免疫吸附试验（ELISA）法分别检测90例肺癌患者，90例良性肺部疾病和100名健康人血中的TuM2-PK、NSE和CYFRA21-1的浓度。结果肺癌组3种指标水平均明显高于良性肺疾病组和健康对照组，差异有统计学意义（P〈0．01）；TuM2-PK诊断肺癌的敏感度为68．9％，特异度为91％；TuM2-PK和NSE联合检测肺癌的阳性率最高为81％。结论TuM2-PK可作为一种新肺癌标志物应用，TuM2-PK和NSE联合检测可以提高对肺癌的阳性诊断。
Objective To evaluate the diagnostic values of TuM2-PK, NSE and CYFRA21-1 tumor marker for lung cancer. Methods The concentration of three markers in plasma was detected by ELISA in 90 lung cancer patients,90 benign lung disease patients and 100 healthy people. Results The concentration of TuM2-PK,NSE and CYFRA21-1 was significantly higher in lung cancer than that in benign lung disease and health controls （P 〈 0.01, respectively）. The diagnostic sensitivity and specificity of tumor M2-PK was 68.9% and 91% respectively. The combined sensitivity of TuM2-PK ＋ NSE （ 81% ） for hmg cancer diagnosis was higher than that of single item or the other combination （ TuM2-PK ＋ CYFRA21- 1 ）. Conclusion TuM2-PK can be used in diagnosis of lung cancer. The combined detection of TuM2- PK ＋ NSE can increase significantly the sensitivity.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2008年第9期1128-1129,共2页
Chinese Journal of Experimental Surgery
关键词
肺肿瘤
诊断
肿瘤标记物
丙酮酸激酶
Lung neoplasm
Diagnosis
Tumor marker
Pyruvatc kinasc
